Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 6/20 | 0.41 |
| ▸ | MTNR1B | P49286 | 6/20 | 0.41 |
| ▸ | DPP4 | P27487 | 1/20 | 0.36 |
| ▸ | PREP | P48147 | 1/20 | 0.36 |
| ▸ | FAP | Q12884 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | ERCC1 | P07992 | 1/20 | 0.31 |
| ▸ | ERCC4 | Q92889 | 1/20 | 0.31 |
| ▸ | FPR3 | P25089 | 1/20 | 0.31 |
| ▸ | FPR2 | P25090 | 1/20 | 0.31 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14445023 | 0.78 | MTNR1A (0.37) | MTNR1AMTNR1BKMT2AEPHX1 | |
| SCHEMBL26147500 | 0.74 | SLC6A2 (0.38) | MTNR1AMTNR1B | |
| SCHEMBL10216977 | 0.73 | MTNR1A (0.36) | MTNR1AMTNR1BDPP4PREPFAP | |
| SCHEMBL24333746 | 0.73 | DPP4 (0.39) | MTNR1AMTNR1BDPP4PREPFAP | |
| SCHEMBL24105941 | 0.73 | MTNR1A (0.36) | MTNR1AMTNR1BDPP4PREPFAP | |
| SCHEMBL1107035 | 0.71 | TDP1 (0.52) | DPP4PREPFAPCYP2D6KMT2A | |
| SCHEMBL20665988 | 0.71 | DPP4 (0.36) | MTNR1AMTNR1BDPP4PREPFAP | |
| SCHEMBL14164120 | 0.70 | EPHX2 (0.39) | MTNR1AMTNR1BKMT2A | |
| SCHEMBL2608915 | 0.70 | CA1 (0.41) | MTNR1AMTNR1BDPP4PREPFAP | |
| SCHEMBL2608926 | 0.70 | CA1 (0.41) | MTNR1AMTNR1BDPP4PREPFAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230150974-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2023-05-18 | — | — | US | disclosed |
| US-20230150974-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2023-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230150974-A1 | COMPOUNDS AND USES THEREOF | VHL, CLN6, TFEB | MTNR1A 3865/4885MTNR1B 3068/4885DPP4 4159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.